Get the Stockscreener App
7.27
1.54%
0.11
After Hours:
7.24
-0.03
-0.41%
Shattuck Labs Inc stock is traded at $7.27, with a volume of 894.44K.
It is up +1.54% in the last 24 hours and up +0.14% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$7.16
Open:
$7.3
24h Volume:
894.44K
Relative Volume:
0.75
Market Cap:
$694.34M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-9.3964
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
+2.83%
1M Performance:
+0.14%
6M Performance:
+92.84%
1Y Performance:
+830.98%
1-Day Range:
$7.215
$7.42
1-Week Range:
$6.90
$7.9399
52-Week Range:
$0.712
$8.33
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
7.27 | 672.38M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
STTK|Shattuck Labs Inc|Price:7.430| - TradingKey
Shattuck Labs Inc (STTK) Institutional Confidence - TradingKey
Shattuck Labs Inc (STTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STTK|Shattuck Labs Inc|Price:7.430|Chg%:+0.340 - TradingKey
Shattuck Labs Inc (STTK) Balance Sheet - TradingKey
Shattuck Labs Inc (STTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Shattuck Labs Inc (STTK) Cash Flow - TradingKey
STTK Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentFull Year Guidance - dars.gov.et
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Globe and Mail
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Motley Fool
STTK Initiated Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
JPMorgan Initiates Shattuck Labs at Overweight With $10 Price Target - marketscreener.com
JPMorgan reiterates Shattuck Labs stock rating on DR3 program By Investing.com - Investing.com Canada
JPMorgan reiterates Shattuck Labs stock rating on DR3 program - Investing.com
Shattuck Labs Inc (STTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Redmile Group, LLC Increases Stake in Shattuck Labs Inc - GuruFocus
Shattuck Labs Inc. (STTK) Drops Sharply as Biotech Sector Faces HeadwindsIron Condor Alert - dars.gov.et
STTK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Form 13D/A Shattuck Labs For: 20 July By Investing.com - Investing.com Nigeria
STTK stock trades steady as Shattuck Labs highlights cash position and clinical progress - Ad-hoc-news.de
Form 13D/A Shattuck Labs For: 17 July By Investing.com - Investing.com Nigeria
Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades - Stock Titan
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline UpdateSlideshow (NASDAQ:STTK) 2026-07-08 - Seeking Alpha
Shattuck Labs CTO Abhinav Shukla sells $2,874 in company stock By Investing.com - Investing.com Nigeria
Shattuck Labs CTO Abhinav Shukla sells $2,874 in company stock - Investing.com
Form 4 Shattuck Labs Inc For: 7 July By Investing.com - Investing.com Nigeria
Shattuck Labs (STTK) CTO exercises options and makes small 10b5-1 sale - Stock Titan
Shattuck Labs outlines its oncology platform as investors assess long-term prospects - ad-hoc-news.de
STTKShattuck Labs Inc Options - Finviz
STTK Q1 2026 Earnings: Narrower-Than-Expected Net Loss Boosts Investor SentimentRevenue Warning Signal - dars.gov.et
Shattuck Labs focuses on immunotherapy pipeline as investors watch clinical milestones - Ad-hoc-news.de
Insider Sell: Arundathy Pandite Sells 30,000 Shares of Shattuck Labs Inc (STTK) - GuruFocus
Shattuck Labs cmo Pandite sells $210,300 in company stock - Investing.com UK
Abhinav Shukla, Shattuck Labs CTO, sells $166,131 in stock By Investing.com - Investing.com South Africa
Form 4 Shattuck Labs Inc For: 2 July By Investing.com - Investing.com Canada
Shattuck Labs cmo Pandite sells $210,300 in company stock By Investing.com - Investing.com Australia
Abhinav Shukla, Shattuck Labs CTO, sells $166,131 in stock - Investing.com
Shattuck Labs (NASDAQ: STTK) CTO option exercises and 23,465-share sale disclosed - Stock Titan
Shattuck Labs (STTK) CMO sells 30,000 shares under 10b5-1 plan - Stock Titan
Form 144 Shattuck Labs For: 2 July By Investing.com - Investing.com Nigeria
410-share sale reported by STTK insider (NASDAQ: STTK) via option exercise - Stock Titan
Form 144 Shattuck Labs For: 1 July By Investing.com - Investing.com South Africa
Abhinav A. Shukla (STTK) files to sell 100 common shares via Form 144 - Stock Titan
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Option Exercise |
3.57 |
410 |
1,464 |
86,790 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Sale |
7.01 |
410 |
2,874 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Option Exercise |
3.57 |
23,365 |
83,413 |
109,745 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Option Exercise |
3.57 |
100 |
357 |
86,480 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Sale |
7.08 |
23,365 |
165,424 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Sale |
7.07 |
100 |
707 |
86,380 |
| Pandite Arundathy N. | Chief Medical Officer |
Jun 30 '26 |
Sale |
7.01 |
30,000 |
210,300 |
136,219 |
1.84%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):